The Zelnorm Epidemiologic Study (ZEST): A Cohort Study Evaluating Incidence of Abdominal and Pelvic Surgery Related to Tegaserod Treatment
Earnest, David L
MetadataShow full item record
CitationSeeger, John, Sherry Quinn, David L. Earnest, Anthony J. Lembo, Braden Kuo, Elena Rivero, and Alexander M. Walker. 2012. The Zelnorm epidemiologic study (ZEST): A cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterology 12:171.
AbstractBackground: Pre-marketing clinical studies of tegaserod suggested an increased risk of abdominal surgery, particularly cholecystectomy. We sought to quantify the association between tegaserod use and the occurrence of abdominal or pelvic surgery, including cholecystectomy. Methods: This cohort study was conducted within an insured population. Tegaserod initiators and similar persons who did not initiate tegaserod were followed for up to six months for the occurrence of abdominal or pelvic surgery. Surgical procedures were identified from health insurance claims validated by review of medical records. The incidence of confirmed outcomes was compared using both as-matched and as-treated analyses. Results: Among 2,762 tegaserod initiators, there were 94 abdominal or pelvic surgeries (36 gallbladder): among 2,762 comparators there were 134 abdominal or pelvic surgeries (37 gallbladder) (hazard ratio HR] = 0.70, 95% confidence interval [C.I.] = 0.54-0.91 overall, HR = 0.98, 95% C.I. = 0.62-1.55 for gallbladder). Current tegaserod exposure compared to nonexposure was associated with a rate ratio [RR] of 0.68 (95% C.I. = 0.48-0.95) overall, while the RR was 0.99 (95% C.I. = 0.56-1.77) for gallbladder surgery. Conclusions: In this study, tegaserod use was not found to increase the risk of abdominal or pelvic surgery nor the specific subset of gallbladder surgery.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10609765